| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/14/1999 | EP0643559B1 Diphtheria toxin receptor-binding region |
| 04/14/1999 | EP0621789B1 Pharmaceutical pentapeptide compositions and methods of use thereof |
| 04/14/1999 | EP0605501B1 Method and compositions for the treatment of cerebral palsy |
| 04/14/1999 | EP0550661B1 Uses of gro genes and proteins |
| 04/14/1999 | EP0548200B1 Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
| 04/14/1999 | CN1214083A Mixture of recominant vaccinia vectors as polyenv vaccines for HIV |
| 04/14/1999 | CN1214080A Glycorprotein B of RFHV/KSHV subfamily of herpes viruses |
| 04/14/1999 | CN1214052A Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 04/14/1999 | CN1214050A Human tumor necrosis factor delta and epsilon |
| 04/14/1999 | CN1213963A Method of producing morphologically uniform microcapsules and microcapsules produced by this method |
| 04/14/1999 | CN1213962A Method for solubilising hydrophylic materials (E. G. proteins) in hydrophobic solvent |
| 04/13/1999 | CA2158750C Monoclonal antibodies to casein kinase i polypeptides |
| 04/13/1999 | CA2155129C Combinations of retroviral inhibitors |
| 04/13/1999 | CA2116562C Morphogen-induced modulation of inflammatory response |
| 04/13/1999 | CA1340494C Induction of tolerance to a foreign antigen |
| 04/13/1999 | CA1340491C Interleukin-7 |
| 04/10/1999 | CA2246632A1 Novel mure |
| 04/10/1999 | CA2225180A1 Non-mammalian mesoderm induction early response (mier) gene family |
| 04/10/1999 | CA2212991A1 Invertebrate mesoderm induction early response (mier) gene family |
| 04/09/1999 | CA2246635A1 Novel glucosaminidase |
| 04/08/1999 | WO1999016889A1 Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment |
| 04/08/1999 | WO1999016888A2 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 04/08/1999 | WO1999016885A1 Killer t cell receptor recognizing human immunodeficiency virus |
| 04/08/1999 | WO1999016883A2 STABILIZATION OF ENVELOPE GLYCOPROTEIN TRIMERS BY DISULFIDE BONDS INTRODUCED INTO A gp41 GLYCOPROTEIN ECTODOMAIN |
| 04/08/1999 | WO1999016881A1 Antigen protein and nucleic acid coding for said protein |
| 04/08/1999 | WO1999016877A1 Amino-terminally truncated rantes as chemokine antagonists |
| 04/08/1999 | WO1999016876A1 Amino-terminally truncated mcp-2 as chemokine antagonists |
| 04/08/1999 | WO1999016875A1 A method for selectively controlling membrane protein display and protein secretion in eukaryotic cells |
| 04/08/1999 | WO1999016874A1 Nucleic acids coding for proteins capable of interacting with presenilins |
| 04/08/1999 | WO1999016871A2 Nucleic acid catalysts with endonuclease activity |
| 04/08/1999 | WO1999016870A1 Secreted protein zsig-11 |
| 04/08/1999 | WO1999016792A1 A polypeptides inhibiting binding between bone sialoprotein ans staphylococcal cells |
| 04/08/1999 | WO1999016791A2 Compounds and methods for regulating cell adhesion |
| 04/08/1999 | WO1999016790A1 Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis |
| 04/08/1999 | WO1999016789A1 Apoptosis-related compounds and their use |
| 04/08/1999 | WO1999016787A1 Cell death agonists |
| 04/08/1999 | WO1999016784A1 Ras-binding protein (pre1) |
| 04/08/1999 | WO1999016745A1 Novel vitamin d derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments |
| 04/08/1999 | WO1999016710A1 Immunogenic conjugated polypeptide for treatment of herpes simplex virus |
| 04/08/1999 | WO1999016469A1 Altered dna synthesome components as biomarkers for malignancy |
| 04/08/1999 | WO1999016465A1 Method for inhibiting tumor angiogenesis in a living subject |
| 04/08/1999 | WO1999016464A1 Modulation of nitric oxide production |
| 04/08/1999 | WO1999016463A1 Preventives or remedies for ischemic diseases |
| 04/08/1999 | WO1999016462A1 Remedies for diseases caused by insulin resistance |
| 04/08/1999 | WO1999016461A1 Antistress agents and functional foods |
| 04/08/1999 | WO1999016460A2 Apolipoprotein e/growth factor complexes and methods of use |
| 04/08/1999 | WO1999016459A1 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 04/08/1999 | WO1999016458A1 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 04/08/1999 | WO1999016457A2 Novel composition for treating, preventing and/or delaying ischemic cell death |
| 04/08/1999 | WO1999016455A1 Mannose receptor bearing cell line and antigen composition |
| 04/08/1999 | WO1999016445A1 Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
| 04/08/1999 | WO1999016427A1 Active agent transport systems |
| 04/08/1999 | WO1999016426A2 Multilamellar coalescence vesicles (mlcv) containing biologically active compounds |
| 04/08/1999 | WO1999016417A1 Buccal, polar and non-polar spray or capsule |
| 04/08/1999 | WO1999016409A2 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 04/08/1999 | WO1999016408A2 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 04/08/1999 | WO1999016406A2 Therapeutic method |
| 04/08/1999 | WO1999009161A8 Pancreas-derived plasminogen activator inhibitor |
| 04/08/1999 | WO1999006549A3 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN TESTIS AND OTHER TISSUES |
| 04/08/1999 | WO1999006439A3 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM |
| 04/08/1999 | WO1999006438A3 Compounds with anti-ks and anti-hiv activity |
| 04/08/1999 | WO1999005269A3 Transcriptional silencer protein nrf |
| 04/08/1999 | WO1999004752A9 Methods for treating skin pigmentation |
| 04/08/1999 | WO1999004026A3 Lentiviral vectors |
| 04/08/1999 | WO1999003987A3 Syncytial respiratory virus epitopes and antibodies comprising them, useful in diagnosis and therapy |
| 04/08/1999 | WO1999003882A3 Human leukocyte calcium activated potassium channel polypeptide |
| 04/08/1999 | WO1999003508A3 METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF |
| 04/08/1999 | WO1999003489A3 Methods and compositions for regulating nuclear trafficking of proteins |
| 04/08/1999 | WO1999003488A3 Biologically active peptides with reduced toxicity in animals and a method for preparing same |
| 04/08/1999 | WO1999000411A3 Two new wd-40 proteins |
| 04/08/1999 | WO1998058057A9 Compositions inducing cleavage of rna motifs |
| 04/08/1999 | WO1998058056A9 Cartilage growth agent |
| 04/08/1999 | WO1998057993A9 Secretory immunoglobulin produced by single cells and methods for making and using same |
| 04/08/1999 | WO1998057664A9 Interleukin converting enzyme (ice) and central nervous system damage |
| 04/08/1999 | WO1998056936A9 Regulatory sequences involved in hypoxia regulated gene expression and uses thereof |
| 04/08/1999 | WO1998056919A9 Methods and reagents for vaccination which generate a cd8 t cell immune response |
| 04/08/1999 | WO1998056913A9 Smad6 and uses thereof |
| 04/08/1999 | WO1998056410A9 Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence |
| 04/08/1999 | WO1998055652A9 Inhibition of hiv replication using a mutated transfer rna primer |
| 04/08/1999 | WO1998055638A9 Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof |
| 04/08/1999 | WO1998055141A9 Methods and products for inducing apoptosis in neuroendocrine cells with macrophage stimulating protein |
| 04/08/1999 | WO1998055105A9 Fibrinogen-coated microspheres |
| 04/08/1999 | WO1998054333A3 Mammalian caax processing enzymes |
| 04/08/1999 | WO1998049321A8 Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors |
| 04/08/1999 | WO1998035694A9 A pharmaceutical composition for treating hepatitis b virus (hbv) infection |
| 04/08/1999 | CA2305809A1 Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis |
| 04/08/1999 | CA2305781A1 Nucleic acids coding for proteins capable of interacting with presenilins |
| 04/08/1999 | CA2305686A1 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 04/08/1999 | CA2305681A1 Apoptosis-related compounds and their use |
| 04/08/1999 | CA2305140A1 Novel vitamin d derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments |
| 04/08/1999 | CA2305017A1 Amino-terminally truncated mcp-2 as chemokine antagonists |
| 04/08/1999 | CA2304956A1 Pharmaceutical composition for preventing or treating ischemic diseases |
| 04/08/1999 | CA2304954A1 Killer t cell receptor recognizing human immunodeficiency virus |
| 04/08/1999 | CA2304951A1 Active agent transport systems |
| 04/08/1999 | CA2304931A1 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 04/08/1999 | CA2304827A1 Amino-terminally truncated rantes as chemokine antagonists |
| 04/08/1999 | CA2304814A1 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 04/08/1999 | CA2304813A1 Nucleic acid catalysts with endonuclease activity |
| 04/08/1999 | CA2304805A1 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 04/08/1999 | CA2304720A1 Apolipoprotein e/growth factor complexes and methods of use |